Identifying protein biomarkers and therapeutic targets in psoriasis through integrative genomic, proteomic and transcriptomic analysis
Meena, D.; Chalitsios, C. V.; Huang, J.; Meena, N.; Wu, S.; Smith, A.; Antonatos, C.; Vasilopoulos, Y.; Yarmolinsky, J.; Gill, D.; Dehghan, A.; Tsilidis, K. K.; Tzoulaki, I.
Show abstract
Plasma proteins are promising biomarkers and potential drug targets in psoriasis. We conducted a two-sample Mendelian randomisation analysis integrating protein quantitative trait loci from UK Biobank and deCODE genetics with a psoriasis GWAS meta-analysis of 36,466 cases. To strengthen causal inference, we performed colocalisation analyses to evaluate shared genetic signals and applied summary data-based MR (SMR) with HEIDI testing using expression quantitative trait loci to exclude linkage-driven associations. After correction for multiple testing, 78 circulating proteins showed genetically predicted associations with psoriasis, with 27 demonstrating strong colocalisation (PPH4>80%). Triangulation prioritised 12 Tier 1 proteins, STX4, FLT3, NFKB1, IL18, PRSS53, SPAG1, SGSH, PLAT, RALB, TNFSF11, SPHK2, and STAT3, supported by consistent effects and no heterogeneity. Network profiling and Genome for REPositioning analyses assessed biological connectivity and druggability, revealing enrichment in anatomical therapeutic chemical groups L and B. Single-cell RNA sequencing confirmed cell-type-specific expression and modulation following IL-23 blockade.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.